Form 8-K PUMA BIOTECHNOLOGY, INC. For: Mar 18
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/14/2026
- S&P 500, Dow futures dip as big banks' earnings roll in ahead of CPI data; IBM slides
- IBM plunges 19% as memory capex squeeze derails Q2 earnings
- SK Hynix’s record plunge drags down global chip stocks
- Software stocks tumble: High memory prices cannibalize enterprise tech capex
- Oil up 9% to one-month high as US says it will blockade entire Iranian coastline, all vessels
- IBM misses Q2 targets as mainframe and software sales disappoint
- Goldman Sachs Upgrades NIO (NIO) to Buy
- Wall Street ends lower as Iran tensions dampen risk appetite; chipmakers drop
- BofA Securities on AppLovin: 'Current valuation appears reasonable'
- YPF Energía Eléctrica S.A. files for proposed NYSE IPO
Puma Biotech (PBYI) Provides Update on AstraZeneca (AZN) Litigation
March 19, 2024 4:12 PM EDTOn September 22, 2021, Puma Biotech (NASDAQ: PBYI) and Wyeth LLC (Wyeth), as co-plaintiffs, filed suit against AstraZeneca Pharmaceuticals, LP, AstraZeneca AB (NASDAQ: AZN), and AstraZeneca PLC for infringement of United States Patent Nos. 10,603,314 (the '314 patent) and 10,596,162 (the '162 patent) (Puma Biotechnology, Inc. et al. v. AstraZeneca Pharmaceuticals LP et al., 1:21CV01338 (D. Del. Sep. 22, 2021)). The Companys complaint alleges that AstraZenecas commercial manufacture, use, offer for sale, sale, distribution, and/or importation of Tagrisso®... More
